Search: WFRF:(Facheris M) >
Continuous Subcutan...
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
-
Aldred, Jason (author)
-
Freire-Alvarez, Eric (author)
-
Amelin, Alexander V (author)
-
show more...
-
Antonini, Angelo (author)
-
Bergmans, Bruno (author)
-
- Bergquist, Filip, 1970 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology
-
Bouchard, Manon (author)
-
Budur, Kumar (author)
-
Carroll, Camille (author)
-
Chaudhuri, K Ray (author)
-
Criswell, Susan R (author)
-
Danielsen, Erik H (author)
-
Gandor, Florin (author)
-
Jia, Jia (author)
-
Kimber, Thomas E (author)
-
Mochizuki, Hideki (author)
-
Robieson, Weining Z (author)
-
Spiegel, Amy M (author)
-
Standaert, David G (author)
-
Talapala, Saritha (author)
-
Facheris, Maurizio F (author)
-
Fung, Victor S C (author)
-
show less...
-
(creator_code:org_t)
- 2023
- 2023
- English.
-
In: Neurology and Therapy. - 2193-8253 .- 2193-6536. ; 12:6, s. 1937-1958
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson's disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) with a single infusion site. The efficacy and safety of foslevodopa/foscarbidopa versus oral immediate-release LD/CD was previously demonstrated in patients with PD in a 12-week, randomized, double-blind, phase 3 trial (NCT04380142). We report the results of a separate 52-week, open-label, phase 3 registrational trial (NCT03781167) that evaluated the safety/tolerability and efficacy of 24-hour/day foslevodopa/foscarbidopa CSCI in patients with advanced PD.Male and female patients with levodopa-responsive PD and≥2.5hours of "Off" time/day received 24-hour/day foslevodopa/foscarbidopa CSCI at individually optimized therapeutic doses (approximately 700-4250mg of LD per 24hours) for 52weeks. The primary endpoint was safety/tolerability. Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's Disease Questionnaire (PDQ-39), and EuroQol 5-dimension questionnaire (EQ-5D-5L).Of 244 enrolled patients, 107 discontinued, and 137 completed treatment. Infusion site events were the most common adverse events (AEs). AEs were mostly nonserious (25.8% of patients reported serious AEs) and mild/moderate in severity. At week 52, "On" time without troublesome dyskinesia and "Off" time were improved from baseline (mean [standard deviation (SD)] change in normalized "On" time without troublesome dyskinesia, 3.8 [3.3] hours; normalized "Off" time, -3.5 [3.1] hours). The percentage of patients experiencing morning akinesia dropped from 77.7% at baseline to 27.8% at week 52. Sleep quality (PDSS-2) and quality of life (PDQ-39 and EQ-5D-5L) also improved.Foslevodopa/foscarbidopa has the potential to provide a safe and efficacious, individualized, 24-hour/day, nonsurgical alternative for patients with PD.ClinicalTrials.gov identifier NCT03781167.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Keyword
- Advanced Parkinson’s disease
- Foslevodopa/foscarbidopa
- Levodopa/carbidopa prodrugs
- Motor fluctuations
- Subcutaneous infusion
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Aldred, Jason
-
Freire-Alvarez, ...
-
Amelin, Alexande ...
-
Antonini, Angelo
-
Bergmans, Bruno
-
Bergquist, Filip ...
-
show more...
-
Bouchard, Manon
-
Budur, Kumar
-
Carroll, Camille
-
Chaudhuri, K Ray
-
Criswell, Susan ...
-
Danielsen, Erik ...
-
Gandor, Florin
-
Jia, Jia
-
Kimber, Thomas E
-
Mochizuki, Hidek ...
-
Robieson, Weinin ...
-
Spiegel, Amy M
-
Standaert, David ...
-
Talapala, Sarith ...
-
Facheris, Mauriz ...
-
Fung, Victor S C
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Neurology
- Articles in the publication
-
Neurology and Th ...
- By the university
-
University of Gothenburg